Supplementary Tables S1-S17 from KAT6A and KAT7 Histone Acetyltransferase Complexes Are Molecular Dependencies and Therapeutic Targets in NUP98-Rearranged Acute Myeloid Leukemia

Supplementary Table S1. Exonic mutations/indels in Nup98::Kdm5a;Vav-Cre tumors developing after bone marrow transplant Supplementary Table S2. Exonic mutations/indels in spontaneous Nup98::Kdm5a;Vav-Cre tumors Supplementary Table S3. Enrichment/depletion of gRNAs for in vivo epigentic CRISPR/Cas9 screen Supplementary Table S4. Enrichment/depletion of genes for in vivo epigenetic CRISPR/Cas9 screen Supplementary Table S5. Gene ontology analysis for in vivo epigenetic CRISPR/Cas9 screen Supplementary Table S6. Upregulated gene sets in NUP98::HOXA9 mouse leukemia cells after 72-hour treatment with 2 uM SNDX-5613 + 500 nM PF9363 versus vehicle treatment Supplementary Table S7. Downregulated gene sets in NUP98::HOXA9 mouse leukemia cells after 72-hour treatment with 2 uM SNDX-5613 + 500 nM PF9363 versus vehicle treatment Supplementary Table S8. Statistical analysis of Meis1 ChIPseq peaks Supplementary Table S9. Upregulated gene sets in NUP98::KDM5A AMKL PDX (CPCT0021) after treatment with PF9363 versus vehicle Supplementary Table S10. Downregulated gene sets in NUP98::KDM5A AMKL PDX (CPCT0021) after treatment with PF9363 versus vehicle Supplementary Table S11. Average expression of KAT6A and Menin targets in scRNAseq data Supplementary Table S12. Motif analysis of regions with differentially upregulated accessibility after combination treatment versus vehicle Supplementary Table S13. Motif analysis of regions with differentially downregulated accessibility after combination treatment versus vehicle Supplementary Table S14. Primers used in this study Supplementary Table S15. gRNA sequences used in this study Supplementary Table S16. Antibodies used in this study Supplementary Table S17. Fusion oncoprotein amino acid sequences used in RIME